Meridian Bioscience Profit Margin

Meridian Bioscience posts a profit margin of -0.9% as of December 2022. That compares with 19.14% in the prior-year period — down 104.7% year over year. That is below the Healthcare sector average of 14.34%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Meridian Bioscience's profit margin was 19.14%. The latest reading is -0.9% — a 104.7% year-over-year decrease (period ending December 2022). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 14.34% is typical. Meridian Bioscience's -0.9% is lower that level. That is roughly 106.2% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Meridian Bioscience's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -0.9% as of December 2022; use YoY and peer views to separate noise from signal.

Context for VIVO's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 14.34%), and (3) consistency with growth and profitability. This page covers the first two; Meridian Bioscience's other metric pages and overview cover the third.